CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 10 enrolled
Drug / intervention
[68Ga]PSMA-PET/MRI or PET/CTdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04086966
NCT04086966Phase 1Completed
CompareCT.gov

PSMA-PET/MRI for Radiation Treatment Planning in Patients With Locally Metastatic Prostate Cancer: A Pilot Study

University of Alabama at Birmingham·interventional·Posted Sep 12, 2019·Updated Apr 26, 2024

In Brief

A Phase 1 clinical trial evaluating [68Ga]PSMA-PET/MRI or PET/CT for Metastatic Prostate Cancer. Completed, enrolled 10 participants across 1 site.

Detailed Summary

This pilot study will investigate the use of PSMA-PET/MRI (Positron Emission Tomography/ Magnetic Resonance Imaging)to guide radiation treatment planning in patients with known or suspected locally metastatic prostate cancer at the time of diagnosis. Patients will undergo a single PSMA-PET/MRI (or PET/CT (Computed Tomography) in some circumstances) prior to initiation of treatment. Following development of a PSMA-PET guided radiation treatment plan, therapeutic radiation will be delivered per standard-of-care parameters and assessments of feasibility and tolerability will be performed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Prostate Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedSep 12, 2019
Enrollment StartAug 20, 2020
Primary CompletionFeb 23, 2022
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 6.8 years ago

Interventions

[68Ga]PSMA-PET/MRI or PET/CTdrug

\[68Ga\]PSMA-PET/MRI or PET/CT